[ad_1] SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the…
Tag: NSCLC
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
[ad_1] SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom’s Medicines and Healthcare Products Regulatory…
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
[ad_1] ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the…
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
[ad_1] ROCKVILLE, Md. and SUZHOU, China, June 1, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment…
Racial, Ethnic, Socioeconomic Disparities Identified Among Patients With Cachexia at NSCLC Diagnosis
[ad_1] An analysis of cachexia risk among patients with stage IV non–small cell lung cancer (NSCLC) revealed a higher risk and associated survival detriments among Black and Hispanic patients. The…